Gravar-mail: Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 ((177)Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer